MedPath

Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria

Not Applicable
Completed
Conditions
Malaria
Interventions
Diagnostic Test: NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device
Registration Number
NCT05286359
Lead Sponsor
Abbott Rapid Dx
Brief Summary

This trial is part of a portfolio of studies designed to assess the clinical and operational performance of Abbott's NxTekTM Malaria Pf Plus and NxTekTM Malaria Pf/Pv Plus Rapid Test Devices.

Detailed Description

A prospective cross-sectional multi-center diagnostic accuracy trial in intended-use settings of the:

1. NxTekTM Malaria Pf/Pv Plus Rapid Test Device for the qualitative detection histidine-rich protein II (HRP-II antigens) and pLDH of Plasmodium falciparum (P.f) and Plasmodium vivax (P.v) malaria in human whole blood.

2. NxTekTM Malaria Pf PlusRapid Test Device for the qualitative detection of histidine-rich protein II (HRP-II antigens) and pLDH of Plasmodium falciparum (P.f) malaria in human whole blood.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1023
Inclusion Criteria
  • Aged 5years old or older
  • Presenting at the trial site with fever or a history of fever (axillary temp ≥ 37.5C) during the preceding 48hours
  • Freely agreeing to participate by providing informed consent (and assent, if applicable)
Exclusion Criteria
  • Presence of symptoms and signs of severe illness and/or central nervous system infections as defined by WHO guidelines.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
NxTekTM Malaria Plus Rapid Diagnostic Test (RDT) DevicesNxTekTM Malaria Pf Plus Rapid Diagnostic Test Device-
Primary Outcome Measures
NameTimeMethod
Assess the sensitivity, specificity, positive and negative predicting values (PPV and NPV) [altogether referred to hereafter as "diagnostic accuracy"] of NxTekTM Malaria Pf Plus6 months

To assess the sensitivity, specificity, positive and negative predicting values (PPV and NPV) \[altogether referred to hereafter as "diagnostic accuracy"\] of NxTekTM Malaria Pf Plus in intended use settings for detecting P.f. infections in capillary whole blood samples collected prospectively from patients with symptoms suggestive of malaria (e.g. febrile).

To assess the diagnostic accuracy of NxTekTM Malaria Pf/Pv Plus.6 months

To assess the diagnostic accuracy of NxTekTM Malaria Pf/Pv Plus in intended use settings for detecting P.f. and P.v. infections in capillary whole blood samples collected prospectively from patients with symptoms suggestive of malaria (e.g. febrile).

Secondary Outcome Measures
NameTimeMethod
Estimates of diagnostic accuracy characteristics with 95% confidence intervals of comparator tests (05FK50, 05FK80, 05FK120, LM)6 months

Estimates of diagnostic accuracy characteristics with 95% confidence intervals of comparator tests (05FK50, 05FK80, 05FK120, LM), using the reference test as standard of truth for the detection of P. falciparum and, when relevant, P.v. infections in patients with symptoms suggestive of malaria

Estimates of diagnostic accuracy characteristics with 95% confidence intervals ofthe index tests for the detection of P.f.infections with hrp2 and/or hrp3 deletions6 months

Estimates of diagnostic accuracy characteristics with 95% confidence intervals of the index tests for the detection of P.f. infections with hrp2 and/or hrp3 deletions in patients with symptoms suggestive of malaria

Trial Locations

Locations (1)

Medical Parasitology Research Unit, Aklilu Lemma Institute of Pathobiology (ALIPB), Addis Ababa University (AAU).

🇪🇹

Addis Ababa, Ethiopia

© Copyright 2025. All Rights Reserved by MedPath